Pages that link to "Q42082392"

The following pages link to Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer (Q42082392):

Displaying 21 items.

• The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer (Q26823733) (← links)
• Targeting bone physiology for the treatment of metastatic prostate cancer (Q26863249) (← links)
• Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer (Q33387322) (← links)
• A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial) (Q33396382) (← links)
• Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. (Q33408380) (← links)
• Recent advances in bone-targeted therapies of metastatic prostate cancer (Q33703763) (← links)
• Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. (Q34662423) (← links)
• Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP. (Q35057029) (← links)
• Castration-resistant prostate cancer: new science and therapeutic prospects (Q35076264) (← links)
• Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study (Q35592471) (← links)
• Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer (Q36840731) (← links)
• Optimal bone health management strategies in patients with prostate cancer (Q37080734) (← links)
• Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. (Q37166534) (← links)
• Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer (Q37193613) (← links)
• Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival (Q37662701) (← links)
• Bone metastasis in prostate cancer: emerging therapeutic strategies. (Q37873719) (← links)
• The Role of Bone-Seeking Radionuclides in the Palliative Treatment of Patients with Painful Osteoblastic Skeletal Metastases (Q38001275) (← links)
• Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study. (Q47684583) (← links)
• Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'. (Q48107105) (← links)
• Optimal management of bone metastases in prostate cancer. (Q53266501) (← links)
• Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial (Q56516395) (← links)